Published in Int J Nanomedicine on October 06, 2016
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Glutathione metabolism and its implications for health. J Nutr (2004) 6.27
Crystal structure of mitochondrial respiratory membrane protein complex II. Cell (2005) 3.44
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem (2006) 2.55
Paclitaxel and its formulations. Int J Pharm (2002) 2.34
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst (2007) 2.00
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 1.95
Multiple drug resistance mechanisms in cancer. Mol Biotechnol (2010) 1.84
Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release (2011) 1.52
Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res (1999) 1.51
Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials (2012) 1.39
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm (2007) 1.28
Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm (2006) 1.21
The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials (2006) 1.21
Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem (1992) 1.16
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials (2008) 1.14
Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res (2003) 1.12
Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials (2011) 1.11
Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials (2010) 1.08
Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther (1999) 1.07
Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release (2011) 1.06
Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev (1999) 1.04
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J Control Release (2005) 1.01
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials (2008) 1.00
Methylmalonic acid, a biochemical hallmark of methylmalonic acidurias but no inhibitor of mitochondrial respiratory chain. J Biol Chem (2003) 0.99
Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin. Biomaterials (2009) 0.98
Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier. Biomaterials (2010) 0.96
Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol (1999) 0.93
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol (2001) 0.91
Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J (2010) 0.91
Cationic amphiphilic drugs self-assemble to the core-shell interface of PEGylated phospholipid micelles and stabilize micellar structure. Philos Trans A Math Phys Eng Sci (2013) 0.89
Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors. Biomaterials (2012) 0.88
Calcium signalling-dependent mitochondrial dysfunction and bioenergetics regulation in respiratory chain Complex II deficiency. Cell Death Differ (2010) 0.87
Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance. Mol Pharm (2013) 0.86
Effect of alpha-tocopherol and tocopherol succinate on lipid peroxidation in equine spermatozoa. Anim Reprod Sci (2005) 0.86
Rapidly disassembling nanomicelles with disulfide-linked PEG shells for glutathione-mediated intracellular drug delivery. Chem Commun (Camb) (2011) 0.86
Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol (1997) 0.86
Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles. Yakugaku Zasshi (2008) 0.84
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol (2001) 0.84
Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells. Mol Biosyst (2014) 0.83
Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating. J Control Release (2011) 0.83
Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials (2015) 0.83
Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology (2012) 0.82
Paclitaxel and Tacrolimus Coencapsulated Polymeric Micelles That Enhance the Therapeutic Effect of Drug-Resistant Ovarian Cancer. ACS Appl Mater Interfaces (2016) 0.81
ROS-triggered and regenerating anticancer nanosystem: an effective strategy to subdue tumor's multidrug resistance. J Control Release (2014) 0.81
Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer (1994) 0.80
Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronal and glial cells. Biochem Pharmacol (2001) 0.80
Nano-cage-mediated refolding of insulin by PEG-PE micelle. Biomaterials (2015) 0.80
PSC833: initial clinical results in refractory ovarian cancer patients. Curr Opin Oncol (1998) 0.79
Low dose (-)deprenyl is cytoprotective: it maintains mitochondrial membrane potential and eliminates oxygen radicals. Life Sci (2005) 0.79
Curcumin-loaded PLGA nanoparticles conjugated with anti- P-glycoprotein antibody to overcome multidrug resistance. Asian Pac J Cancer Prev (2014) 0.78
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study. Ann Oncol (1994) 0.78
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs (1999) 0.77
PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun (1999) 0.76